期刊名称 Expert Opinion on Pharmacotherapy
期刊缩写 EXPERT OPIN PHARMACO
学科分类 生命科学、医学
出版周期 月刊
审稿速度 1 个月 （平均）
投稿命中率 不详
期刊主页 http://informahealthcare.com/loi/eop
ISSN 号 1465-6566
IF 趋势 2005 2006 2007 2008 2009 2010 2011 2012
1.823 1.733 1.703 2.077 2.018 2.403 3.205 2.86
被收录情况 1. Science Citation Index Expanded
2. Current Contents - Clinical Medicine
PubSci评语 偏药理。论文发表周期有三个选项，超快和快速发表需要交纳一定费用，一般发表方式周期长达20周，但不需缴费。
期刊简介 Expert Opinion on Pharmacotherapy是一个同行评审的，发表关于最新批准或即将获批的化合物综述和原创性论文的国际期刊。主要关注如下领域：1. 从临床三期到进入药典五年以上且针对特定疾病的药物综述，以及它们对将来治疗策略的潜在影响。2. 从临床和制药数据角度对特定药进行药物评估 3. 处于临床三四期制剂临床调查研究结果。
投稿注意事项 特别提醒：根据周期长短，有三种论文发表方式。FastTrack方式最短，提交到在线发表5-7周；其次是RapidTrack方式，提交到发表需要10-12周，这两种方式都需要交纳一定费用。最后是StandardTrack方式，提交到发表的周期在20周左右，不需交纳费用。
一般注意事项：
Aims & Scope
2012 ISI Impact Factor: 2.86
Expert Opinion on Pharmacotherapy ranks #83 of 260 in the Pharmacology & Pharmacy category in the 2012 ISI Journal Citation Reports.
Expert Opinion on Pharmacotherapy (ISSN 1465-6566 [print], 1744-7666 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on newly approved/near to launch compounds, providing expert opinion on the likely impact of these new agents on existing pharmacotherapy of specific diseases.
The Editors welcome:
Reviews covering new drugs/drug classes for specific diseases, from development Phase III to those that have been available to pharmacopoeia for up to 5 years, and their potential impact on future treatment strategies
Drug Evaluations reviewing the clinical and pharmacological data on a particular drug
Original Research papers reporting the results of clinical investigations on agents that are in Phase III and IV clinical trials and pharmacologically based studies with a strong link to clinical practice
The audience consists of research and development, regulatory and marketing decision makers in the pharmaceutical industry and decision makers in healthcare provision.
Indexing
Chemical Abstracts (CODEN: EOPHF7), Current Contents®/Clinical Medicine, EMBASE/Excerpta Medica, Index to Scientific Reviews, Index Medicus/Medline, ISI Alerting Services™, Science Citation Index Expanded™
Editorial Staff
Commissioning Editor: Amina Abdel Latif
Editorial Advisory Board
Overseeing the editorial content and development of the journal is an Editorial Board, composed of many of the worlds leading experts within the area of drug research and development.
For information about the Editorial Board please click here.
Instructions for Authors / Submission Guidance
To submit a manuscript click here
Guidelines for authors can be found below:
Reviews and other article types
Drug Evaluations
Treatment Evaluations
Original Research
Pharmacoeconomics Evaluations
Letters to the Editor
With every submission, please complete a disclosure form.
Original research and other unsolicited articles:
The Commissioning Editor, under the advice of the Editorial Board, solicits the majority of articles published in Expert Opinion on Pharmacotherapy. However, the submission of Original Research and other unsolicited articles is welcomed, for which we offer the following service options:
FastTrack is the ultra-rapid publication service option offering prioritised peer review and expedited publication of manuscripts (submission to online publication in 5-7 weeks).
RapidTrack is the other prioritised option, offering submission to online publication in 10-12 weeks. A publication support fee is required for these service levels.
StandardTrack offers a non-prioritised service, where accepted manuscripts achieve submission to online publication in up to 20 weeks. There are no publication fees for this service.
Pre-submission contact:
Expert Opinion on Pharmacotherapy welcomes authors contacting the Editorial Offices ahead of formal submission and specially encourages prior contact for FastTrack submissions where a particular publication deadline is desired. If you are interested in submitting an article, please contact Amina Abdel Latif.
Peer review:
All manuscripts are subject to confidential and anonymous (double-blinded) peer review by at least two independent referees. Comments remain confidential and are shared only with the corresponding author or submitting party. For our peer review guidelines, please click here. For Original Research peer review guidelines, please click here.
For full details of our editorial policies, including NIH-funded papers, please refer to our policy document and resources for authors.
Publishing Services
Click here to read more about the benefits of publishing with Expert Opinion
Read More: http://informahealthcare.com/page/eop/Description#Instructions
编辑部信息 所在地： 国家 英国
Editor in Chief
Dimitri Mikhailidis: The Royal Free Hospital, UK
Editorial Advisory Board
Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis
Piérard G: University of Liege, Belgium
Reginster J-Y: University of Liege, Belgium
Wollina U: Academic Teaching Hospital Dresden-Friedrichstadt, Germany
Anti-infectives
De Clercq E: Rega Institut, Belgium
Kirst HA: Eli Lilly, USA
Lode H: Charité-Universitätsmedizin Berlin, Germany
Nicolau D: Hartford Hospital, UK
Cardiovascular
Banach M: University of Lodz, Poland
Bramlage P: Institute for Cardiovascular Pharmacology and Epidemiology, Germany
Davidson MH: Radiant Research, USA
Di Girolamo G: University of Buenos Aires, Argentina
Doggrell S: Charles Darwin University, Australia
Gurbel P: Sinai Center for Thrombosis Research, USA
Krum H: Monash University, Australia
Schwarz ER: David Geffen School of Medicine at UCLA, USA
Renal, Endocrine & Metabolic
Di Girolamo G: University of Buenos Aires, Argentina
Khastgir J: Bristol Urological Institute, UK
Perimenis P: University of Patras, Greece
Central & Peripheral Nervous Systems
Findling R: Case Western University, USA
Fountoulakis KN: Aristotle University of Thessaloniki, Greece
Grossberg G: Saint Louis University School of Medicine, USA
Irwin MG: University of Hong Kong
Kasper S: University of Vienna, Austria
Marcus D: University of Pittsburgh, USA
Theoharides T: Tufts University School of Medicine, USA
Pharmacoeconomics
Greenberg P: Analysis Group Economics, USA
Lee K: The Chinese University of Hong Kong, China
Sculpher M: University of York, UK
You JH: The Chinese University of Hong Kong
Oncologic
Kelly C: M.D. Anderson Cancer Center, USA
Montemurro F: IRCC Candiolo, Italy
Tonini G: University Campus Bio-Medico, Italy Dasanu C: University of Connecticut School of Medicine, USA
Pharmacogenomics
Marsh S: Washington University School of Medicine, USA
Read More: http://informahealthcare.com/page/eop/EditorialAdvisoryBoard
网友投稿经验整理：
研究方向：药理
二月份投稿，四月份接收。挺好。
贡献者： ppswppp
SCI(2010)：2.403
3分边缘的杂志，影响因子变化不大，相对来说，适合咱们中国人投稿
贡献者：
SCI(2011)：3.205 SCI(2010)：2.403
这些期刊相当重要，我们一定要珍惜，现在不少单位都要求影响因子大于3分才能毕业，我给大家加上来
贡献者：wangjs
